Mood Disorders

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.

What is new in research on bipolar disorder?

Here’s a look back at selections from our March content series on mood disorders.

This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.

What is the Clubhouse model of psychosocial rehabilitation, and how can it benefit both patients and clinicians alike?

“Our patients, our field, and our integrity demand a better explanation of what happened in STAR*D than what has thus been provided.”

In this CME article, review the principles and applications of both invasive and noninvasive neuromodulation techniques for the treatment of mood disorders.

Here's how embracing a comprehensive, patient-centered approach and staying informed about emerging treatments can help mental health professionals make a difference in the lives of patients with TRD.

The Psychiatric Times Special Report on Treatment-Resistant Depression includes expert discussions on how clinicians can manage major depressive disorder and treatment-resistant depression in patients who do not achieve wellness right away.

Take a look back at our recent coverage relating to our March content theme.

Write to us now to be part of our series focused on mood disorders this month.

Neuropsychiatric disorders regularly occur following traumatic brain injury and are often diagnosed within the first year postinjury. Diagnosis and treatment of neuropsychiatric disorders can be difficult due to a number of interacting factors, such as preinjury psychiatric history, lesion location, injury severity, substance misuse, and psychosocial complications. Clinicians should use a highly individualized approach to diagnosis and treatment planning.

Future use of a 12-hour standardized lithium serum concentration notation: the first step towards more interpretable scientific literature and the return of the therapeutic importance of lithium.

These partnerships aim to address the mental health needs of underserved populations, including individuals with clinical depression, anxiety, and mood disorders.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

Psychiatric Times chats with new Mood Disorders Section Editor Gus Alva, MD, about his new role, his interest in mood disorders, and his love of psychiatry.

Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?

The Psymatic Treatment Optimizer facilitates selecting agents ranked by adverse-effect profile with consideration of patient preference and tolerance.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.

What is new in research on sleep?

How does a patient process their illness and move their way to healing and even creativity?

Black mothers in the US experience far worse outcomes. Here’s what clinicians need to know.

What is the association between the gut microbiome and response to SSRIs in patients with depression?

1 in 5 respondents reported using psychedelic drugs for the purpose of self-treating anxiety, depression, or other mental illnesses.

Check out the evidence for a modest effect over 1 year of clozapine dose on weight.

PME affects many women, yet it remains under-recognized in clinical practice and in research.